Clinical trial
A Phase II Study of Isolated Hepatic Perfusion (IHP) in Patients With Ocular…
NCT00062933 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00062933 |
|---|---|
| Title | A Phase II Study of Isolated Hepatic Perfusion (IHP) in Patients With Ocular Melanoma |
| Official title | A Phase II Study of Isolated Hepatic Perfusion (IHP) With Melphalan Followed by Temozolomide for Subjects With Unresectable Hepatic Metastases From Ocular Melanoma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Melanoma |
| Intervention type | Procedure |
| Interventions | Laparotomy |
| Enrollment | 40 |
| Start date | Jun 1, 2003 |
| Primary completion | Sep 1, 2007 |
| Completion | Mar 1, 2008 |
| First posted | Jun 18, 2003 |
| Last update posted | Aug 20, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: